Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

SANOFI : Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 01:09am EST

PRESS RELEASE

Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe - Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine - Lyon, France - April 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN

and NYSE: SNY), announced today that the European Commission approved Sanofi Pasteur's 6-in-
1 pediatric vaccine HexyonTM/Hexacima® (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima® is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name HexyonTM in Western European countries* by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima® in Eastern European countries by Sanofi Pasteur.

"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."

Key benefits of HexyonTM/Hexacima® vaccine:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
02/15SANOFI : Iqvia quietly purchased UK-based NLP provider Linguamatics
AQ
02/14SANOFI : Tech startups have two days left to enter the Sanofi Healthcare Innovat..
AQ
02/13SANOFI : PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent l..
AQ
02/12REGENERON PHARMACEUTICALS : and Sanofi Offer Praluent at a New Reduced U.S. List..
AQ
02/12SANOFI : appoints Ameet Nathwani Chief Digital Officer
GL
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/11SANOFI : and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list p..
PR
02/08SANOFI : House panels want raps vs Aquino, Abad, Garin, others over dengue-vacci..
AQ
02/07GLOBAL MARKETS LIVE : General Motors, Sonos, Chipotle Mexican Grill, Publicis ....
More news
Financials (€)
Sales 2019 36 145 M
EBIT 2019 9 294 M
Net income 2019 5 244 M
Debt 2019 15 151 M
Yield 2019 4,15%
P/E ratio 2019 17,28
P/E ratio 2020 15,36
EV / Sales 2019 3,02x
EV / Sales 2020 2,78x
Capitalization 93 861 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 83,4 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-0.56%106 006
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536